Health ❯ Healthcare

Pharmacology

Drug Development Medications Drug Safety Drug Interactions Antibiotics Drug Therapy Diabetes Medications Drug Efficacy Drug Treatments GLP-1 Receptor Agonists

Kamuvudine K-9 Reverses MS-Like Paralysis and Vision Loss in Mice

Blocking inflammasome activation, K-9 preserved myelin and lowered a blood marker of nerve injury, supporting planned human testing.

Viking’s VK2735 Shows Durable Weight Loss With Less‑Frequent Dosing

Gotistobart Extends Survival in Early PRESERVE‑003 Update

Proteomic Signatures in Children Predict Adult Cardiometabolic and Kidney Disease Risk

AstraZeneca's Tozorakimab Cuts COPD Flare‑Ups in Two Phase 3 Trials

Semaglutide Linked to Fewer Asthma Attacks and COPD Flare‑Ups in Large UK Analysis

Semaglutide Extends Lifespan and Slows Ageing in Older Female Mice

MIT-Led Atlas Maps 31 Neuronal Subtypes in the Human Striatum

AAN and AHS Update Guideline on Migraine Prevention

FDA Expands Mounjaro Label to Include Cardiovascular Risk Reduction

Atorvastatin Cuts Major Cardiovascular Events by 30% in Adults 70 and Older

Milvexian Fails to Cut Heart Attack, Stroke or Death After Acute Coronary Syndrome

Immediate Evolocumab at PCI Cuts LDL but Fails to Lower One‑Year Events

Edoxaban Shows No Net Benefit for Atrial Fibrillation Patients After Intracranial Haemorrhage

Two NEJM Trials Show Antiplatelet Monotherapy Risks Depend on Drug and Timing

DOACs Cut Stroke and Cardiovascular Events Without Raising Major Bleeding in Intermediate‑Risk AF, SINGLE‑AF Finds

Missed Doses Largely Erase Cardiovascular Benefit of Blood Pressure Drugs, Meta‑Analysis Finds

Brazilian Pediatricians Warn Against GLP‑1 ‘Weight‑loss Pens’ Use in Children and Teens

UC Irvine Proposes Mitochondrial‑Targeted, Steroid‑Sparing Strategy for CAR T Neurotoxicity

Novo Nordisk’s Ziltivekimab Lowers Inflammation but Fails to Reduce Major Heart Events